Introduction: Nowadays, we need to deal with heart transplanted patients for other medical concerns. So, it is important to see in detail different aspects and modalities of their care during other types of surgery. A transplant team will carefully monitor each heart trans-plant recipient and should be possible to seek information on the patient’s overall status. They will be able to inform on the most recent investigations (ECG to assess graft function, recent biopsy for rejection, angiography for coronaries, etc.).
Case report: Our patient, a 65-year-old lady underwent heart transplantation 5 years before. The cardiac situation was stable and she was doing fine. She was recovered in the gynaecological clinic with a diagnosis of vaginal prolapse with surgical indication General anaesthesia was done with fentanyl 7 ml, pavulon 4 mg, propofol 200 mg and sevoflurane 1.5-2.2%. The patient was monitored during surgery with SpO2, ECG, IBP, CVP. The operation technique was open of vaginal plastic repaire.
Discussion: By 3 months, most recipients of heart transplant came under New York Heart Association (NYHA) I class. The last UK national survey about health-related quality of life after cardiac transplantation indicates that, 1 year after surgery, there is an improvement in quality of life (60% are much better; 28% somewhat better) and there is no deterioration in general health at 3–5 years, except that many of them have symptoms compatible with depression.
Conclusion: Perioperative care of heart transplant recipients will entail a greater attention to maintaining an adequate preload and vascular tone, to avoiding infections and to being aware of the multiple side effects of immunosuppressive therapy. References and recommended reading papers of particular interest, published within the annual period of review, have been highlighted as of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue.
Klein DG. Current trends in cardiac transplantation. Crit Care Nurs Clin North Am 2007; 19:445–460; vii.
Bjerke R, Mangione M. Asystole after intravenous neostigmine in a heart transplant recipient. Can J Anaesth 2001; 48:305–307.
Bengel F, Ueberfuhr P, Schiepel N, et al. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. New Engl J Med 2001; 345:731 – 738.
Allard R, Hatzakorzian R, Deschamps A. Decreased heart rate and blood pressure in a recent cardiac transplant patient after spinal anesthesia. Can J Anesth 2004; 51:829–833.
Cheng DCH, Ong DD. Anesthesia for noncardiac surgery in heart-transplanted patients. Can J Anaesth 1993; 40:981–986. This classic manuscript describes anesthesia in heart recipients.
Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006; 25:869–879.
Fazel S, Everson A, Stitt LW, et al. Predictors of general surgical complications after heart transplantation. J Am Coll Surg 2001; 193:52.
Marzoa R, Crespo-Leiro MG, Paniagua MJ, et al. Late noncardiac surgery in heart transplant patients. Transplant Proc 2007; 39:2382–2384.A useful source listing the most common indications and complications of noncardiac surgery in heart transplant patients.
Tan CD, Baldwin WM 3rd, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med 2007; 131:1169–1191.
Hiemann NE, Knosalla C, Wellnhofer E, et al. Quilty in biopsy is associated with poor prognosis after heart transplantation. Transpl Immunol 2008; 19:209 – 214.
Hiemann NE, Knosalla C, Wellnhofer E, et al. Quilty indicates increased risk for micro vasculopathy and poor survival after heart transplantation. J Heart Lung Transplant 2008; 27:289–296.
Hsieh GR, Schnickel GT, Garcia C, et al. Inflammation/oxidation in chronic rejection: apolipoprotein a-I mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007; 84:238–243.
Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now? Nat Clin Pract Cardiovasc Med 2006; 3:203–212.
Celik S, Doesch A, Erbel C, et al. Beneficial effects of omega-3 fatty acids on sirolimus or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 2008; 86:245–250.This article showed good results with diet in order to prevent hypertriglyceridemia and protect against cardiac allograft vasculopathy
Mehra M, Uber P, Walther D, et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation. Circulation 2006; 114 (Suppl I): I-21–I-26.
Gustafsson F, Ross H. Proliferation signal inhibitors in cardiac transplantation. Curr Opin Cardiol 2007; 22:111–116.This is the most recent and interesting article about these new drugs and their effects and side effects.
Aqel RA, Wells Bj, Hage FG. Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy. J Heart Lung Transplant 2008; 27:610–615; Epub 2008.
Aguero J, Almenar L, Martinez-Dolz L, et al. Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation. Clin Transplant 2008; 22:98–106.
Van de Beek D, Kremers WK, del Pozo JL, et al. Effects of infectious diseases on outcome after a heart transplant. Mayo Clinic Proc 2008; 83:304 – 308.
Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with the Novo sirolimus versus MMF-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6:986–992.
Al-khaldi A, Robbins RC. New directions in cardiac transplantation. Annu Rev Med 2006; 57:455–471.
Fearon WF, Potena L, Hirohata A, et al. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 2007; 83: 700 – 705.
Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 2008; 22:76–81.
Crespo-Leiro MG, Paniagua MJ, Franco R, et al. Late steroid withdrawal after heart transplantation and incidence of acute rejection. Transplant Proc 2007; 39:2372 – 2374.
Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883–889.
Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant 2007; 26:750–752.
Eisen HJ. Immunosuppression on the horizon. Heart Fail Clin 2007; 3:43 – 49. 28 Aliabadi AZ, Zuckermann AO, Grimm M. Immunosuppressive therapy in older cardiac transplant patients. Drug Aging 2007; 24:913–932.
Kostopanagiotou G, Smyrniotis V, Arkadopoulos N, et al. Anesthetic and perioperative management of adult transplant recipient in nontransplant surgery. Anesth Analg 1999; 89:613–622.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.